R&D channel feed – Endpoints News

R&D channel feed

Alzheon hits another dead end funding its Alzheimer's program, pulls second IPO attempt

7 years ago

Second time's a charm for osteoporosis drug from Amgen, UCB as FDA panel grants its blessing

7 years ago

Dragonfly preps clinical takeoff, inking a collaboration pact with MD Anderson

7 years ago

Aptinyx shares crater as lead drug fails in PhII neuropathic pain study

7 years ago

Five Prime cuts 41 jobs, days before presenting data at ASCO meeting of GI cancers

7 years ago

Merck highlights crucial hit for Keytruda in second-line esophageal carcinoma — but there are also 2 misses

7 years ago

Scoop: Pfizer once again takes out the budget ax, lopping off 150 R&D staffers and 5 preclinical biosimilar drugs

7 years ago

Nebulizer fails PhII COPD study, but Verona plans to march on

7 years ago

Aslan turns focus to biliary tract cancer as lead drug flops in PhII gastric cancer study

7 years ago

AstraZeneca chops 210 workers, closes sites as it looks to concentrate biologics manufacturing in one place

7 years ago

NICE rejects Novartis' migraine drug Aimovig, months after declining to endorse pricey Kymriah for adult use

7 years ago

‘It’s us against the world’: And George Yancopoulos wants you to know they are beating the world — big time

7 years ago

Liz Barrett's bet on UroGen proves timely, as biotech's lead drug scores in key study

7 years ago

Sage shrugs off potential competition in postpartum depression, asserts plan to remain independent

7 years ago

Cheerful mid-stage depression drug data send Axsome stock flying

7 years ago

AstraZeneca names controversial cancer scientist José Baselga to a top R&D post in major shakeup

7 years ago

Allergan joins the great biopharma R&D migration to Cambridge

7 years ago

Sage's oral postpartum depression drug ticks efficacy, safety boxes in key trial, easing fears of fainting risk

7 years ago

Shifting focus, Sanofi agrees to pay Regeneron $462M for an early wrap of their big I/O alliance

7 years ago

Deserted by Takeda, Mersana abandons lead drug

7 years ago

Axing staff and shelving cancer programs, Selecta hopes laser focus on gout will prove a way out

7 years ago

After blueprinting R&D hub, AbbVie dishes out $105M for CD39 pact with Tizona's new CEO from Roche

7 years ago

Takeda builds arsenal for immuno-oncology research, creates cell therapy group

7 years ago

Merck goes all-in on a late-stage NASH drug from NGM as development race heats up

7 years ago

First page Previous page 255 256 257258259 260 261 Next page Last page